Logo image of IPH.PA

INNATE PHARMA SA (IPH.PA) Stock Fundamental Analysis

Europe - EPA:IPH - FR0010331421 - Common Stock

1.58 EUR
-0.09 (-5.16%)
Last: 9/19/2025, 7:00:00 PM
Fundamental Rating

2

IPH gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 75 industry peers in the Biotechnology industry. Both the profitability and financial health of IPH have multiple concerns. IPH is not valued too expensively and it also shows a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

IPH had negative earnings in the past year.
In the past year IPH has reported a negative cash flow from operations.
IPH had negative earnings in each of the past 5 years.
IPH had a negative operating cash flow in each of the past 5 years.
IPH.PA Yearly Net Income VS EBIT VS OCF VS FCFIPH.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M 150M 200M

1.2 Ratios

With a Return On Assets value of -44.54%, IPH is not doing good in the industry: 62.67% of the companies in the same industry are doing better.
IPH's Return On Equity of -560.01% is on the low side compared to the rest of the industry. IPH is outperformed by 69.33% of its industry peers.
Industry RankSector Rank
ROA -44.54%
ROE -560.01%
ROIC N/A
ROA(3y)-25.61%
ROA(5y)-23.47%
ROE(3y)-227.3%
ROE(5y)-154.41%
ROIC(3y)N/A
ROIC(5y)N/A
IPH.PA Yearly ROA, ROE, ROICIPH.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100 -200 -300 -400 -500

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for IPH so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
IPH.PA Yearly Profit, Operating, Gross MarginsIPH.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100 -200 -300 -400

More info and screens

3

2. Health

2.1 Basic Checks

IPH does not have a ROIC to compare to the WACC, probably because it is not profitable.
IPH has more shares outstanding than it did 1 year ago.
IPH has more shares outstanding than it did 5 years ago.
IPH has a worse debt/assets ratio than last year.
IPH.PA Yearly Shares OutstandingIPH.PA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
IPH.PA Yearly Total Debt VS Total AssetsIPH.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

2.2 Solvency

Based on the Altman-Z score of -4.82, we must say that IPH is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -4.82, IPH is doing worse than 68.00% of the companies in the same industry.
IPH has a Debt/Equity ratio of 8.02. This is a high value indicating a heavy dependency on external financing.
The Debt to Equity ratio of IPH (8.02) is worse than 72.00% of its industry peers.
Industry RankSector Rank
Debt/Equity 8.02
Debt/FCF N/A
Altman-Z -4.82
ROIC/WACCN/A
WACC6.68%
IPH.PA Yearly LT Debt VS Equity VS FCFIPH.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M 150M 200M

2.3 Liquidity

A Current Ratio of 2.60 indicates that IPH has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 2.60, IPH is in line with its industry, outperforming 57.33% of the companies in the same industry.
A Quick Ratio of 2.60 indicates that IPH has no problem at all paying its short term obligations.
The Quick ratio of IPH (2.60) is better than 62.67% of its industry peers.
Industry RankSector Rank
Current Ratio 2.6
Quick Ratio 2.6
IPH.PA Yearly Current Assets VS Current LiabilitesIPH.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

More info and screens

4

3. Growth

3.1 Past

The earnings per share for IPH have decreased strongly by -549.63% in the last year.
The Revenue for IPH has decreased by -75.68% in the past year. This is quite bad
Measured over the past years, IPH shows a very negative growth in Revenue. The Revenue has been decreasing by -28.80% on average per year.
EPS 1Y (TTM)-549.63%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-163.49%
Revenue 1Y (TTM)-75.68%
Revenue growth 3Y1.38%
Revenue growth 5Y-28.8%
Sales Q2Q%-73.85%

3.2 Future

The Earnings Per Share is expected to grow by 9.38% on average over the next years. This is quite good.
The Revenue is expected to grow by 43.06% on average over the next years. This is a very strong growth
EPS Next Y189.51%
EPS Next 2Y62.54%
EPS Next 3Y9.38%
EPS Next 5YN/A
Revenue Next Year172.13%
Revenue Next 2Y90.19%
Revenue Next 3Y29.35%
Revenue Next 5Y43.06%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
IPH.PA Yearly Revenue VS EstimatesIPH.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 100M 200M 300M
IPH.PA Yearly EPS VS EstimatesIPH.PA Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 0.2 -0.2 -0.4 -0.6

More info and screens

4

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for IPH. In the last year negative earnings were reported.
Based on the Price/Forward Earnings ratio of 4.32, the valuation of IPH can be described as very cheap.
97.33% of the companies in the same industry are more expensive than IPH, based on the Price/Forward Earnings ratio.
Compared to an average S&P500 Price/Forward Earnings ratio of 22.86, IPH is valued rather cheaply.
Industry RankSector Rank
PE N/A
Fwd PE 4.32
IPH.PA Price Earnings VS Forward Price EarningsIPH.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
IPH.PA Per share dataIPH.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 -0.4 -0.6

4.3 Compensation for Growth

IPH's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y62.54%
EPS Next 3Y9.38%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for IPH!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

INNATE PHARMA SA

EPA:IPH (9/19/2025, 7:00:00 PM)

1.58

-0.09 (-5.16%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-13 2025-05-13/bmo
Earnings (Next)09-17 2025-09-17/bmo
Inst Owners10.09%
Inst Owner ChangeN/A
Ins Owners2.18%
Ins Owner ChangeN/A
Market Cap145.62M
Analysts77.5
Price Target5.64 (256.96%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)6.8%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)311.93%
EPS NY rev (3m)311.93%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)19.14%
Revenue NY rev (3m)45.55%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 4.32
P/S 11.54
P/FCF N/A
P/OCF N/A
P/B 16.48
P/tB 16.48
EV/EBITDA N/A
EPS(TTM)-0.61
EYN/A
EPS(NY)0.37
Fwd EY23.17%
FCF(TTM)-0.08
FCFYN/A
OCF(TTM)-0.07
OCFYN/A
SpS0.14
BVpS0.1
TBVpS0.1
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -44.54%
ROE -560.01%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-25.61%
ROA(5y)-23.47%
ROE(3y)-227.3%
ROE(5y)-154.41%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score1
Asset Turnover0.11
Health
Industry RankSector Rank
Debt/Equity 8.02
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 19.61%
Cap/Sales 3.1%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.6
Quick Ratio 2.6
Altman-Z -4.82
F-Score1
WACC6.68%
ROIC/WACCN/A
Cap/Depr(3y)22.77%
Cap/Depr(5y)23.45%
Cap/Sales(3y)3.3%
Cap/Sales(5y)8.22%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-549.63%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-163.49%
EPS Next Y189.51%
EPS Next 2Y62.54%
EPS Next 3Y9.38%
EPS Next 5YN/A
Revenue 1Y (TTM)-75.68%
Revenue growth 3Y1.38%
Revenue growth 5Y-28.8%
Sales Q2Q%-73.85%
Revenue Next Year172.13%
Revenue Next 2Y90.19%
Revenue Next 3Y29.35%
Revenue Next 5Y43.06%
EBIT growth 1Y-307.1%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year128.78%
EBIT Next 3Y30.44%
EBIT Next 5YN/A
FCF growth 1Y79.13%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y78.82%
OCF growth 3YN/A
OCF growth 5YN/A